I love this insight:
some rare cancers are strikingly homogeneous with one recurrent driver mutation, which makes them ideal precision medicine targets
🇺🇸 Back in New York for UNGA Week.
The “last mile” conversation continues — exploring what it takes to turn personalised medicine from innovation and ambition into real-world patient benefit.
📍 New York | 23–24 Sept
🔗 Register: https://t.co/gEOKmMiV2w
#UNGA#PatientAccess
⭐️🚨I'm heading to New York @nycgov for the United Nations General Assembly (UNGA) @UN#UNGA26 High-Level Week to join the International Alliance for Personalised Medicine (IAPM) @united4cancer for critical discussions on translating innovation into patient benefit.
⭐️Speaking at United Nations IAPM sessions on September 23–24 with leaders across healthcare, policy, science, & industry on the real work of personalised medicine: closing the gap between discovery & access @OncoAlert@oncodaily
8/8 Thanks to @Timothee_MD Editor-in-chief @myESMO Rare Cancers for the invite @OncoAlert@Alfdoc2
Link to paper: https://t.co/nJlBbCrcF4
Link to Editorial : https://t.co/jTZRwIahS5
🚨Hot off the press 👉Pleased to share an editorial "The rare cancer ‘zebra’ advantage: flipping the script for success in oncology drug development" @myESMO Rare Cancers journal @ESMO_Open@OncoAlert@oncodaily - read the 🧵 @X torial 1/8
https://t.co/jTZRwIahS5